{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:52:20Z","timestamp":1791060740287,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.revmed.2011.12.011","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T14:25:27Z","timestamp":1327933527000},"page":"439-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effets ind\u00e9sirables des inhibiteurs de la pompe \u00e0 proton\u00a0: faut-il craindre de les prescrire au long cours\u00a0?"],"prefix":"10.1016","volume":"33","author":[{"given":"L.","family":"Roulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Vernaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Giostra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Gasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Desmeules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2011.12.011_bib0005","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/archinternmed.2010.64","article-title":"Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users","volume":"170","author":"Katz","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2011.12.011_bib0010","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bmj.39406.449456.BE","article-title":"Overprescribing proton pump inhibitors","volume":"336","author":"Forgacs","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2011.12.011_bib0015","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1365-2125.2000.00262.x","article-title":"The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies","volume":"50","author":"Martin","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0020","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2011.12.011_bib0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis-related fractures","volume":"179","author":"Targownik","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.revmed.2011.12.011_bib0030","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","article-title":"Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative","volume":"170","author":"Gray","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2011.12.011_bib0035","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/MEG.0b013e328348a56a","article-title":"Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis","volume":"23","author":"Ye","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0160-3450(15)32077-8","article-title":"Nutritional and pharmaceutical aspects of calcium supplementation","volume":"2","author":"Carr","year":"1987","journal-title":"Am Pharm"},{"key":"10.1016\/j.revmed.2011.12.011_bib0045","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0899-9007(97)83011-0","article-title":"Calcium and osteoporosis","volume":"13","author":"Nordin","year":"1997","journal-title":"Nutrition"},{"key":"10.1016\/j.revmed.2011.12.011_bib0050","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/07315724.1995.10718522","article-title":"Hypochlorhydria from shortterm omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans","volume":"14","author":"Serfaty-Lacrosniere","year":"1995","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.revmed.2011.12.011_bib0055","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2174\/1381612023393369","article-title":"Selective inhibition of osteoclast vacuolar H+-ATPase","volume":"8","author":"Farina","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.revmed.2011.12.011_bib0060","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/00002018-200932090-00002","article-title":"Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital","volume":"32","author":"Ing-Lorenzini","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.revmed.2011.12.011_bib0065","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1046\/j.1365-2036.2003.01744.x","article-title":"Gastric acid-suppressive therapy and community-acquired respiratory infections","volume":"18","author":"Laheij","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2011.12.011_bib0070","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/archinte.167.9.950","article-title":"Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study","volume":"167","author":"Gulmez","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2011.12.011_bib0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-149-6-200809160-00005","article-title":"Proton-pump inhibitor use and the risk for community-acquired pneumonia","volume":"149","author":"Sarkar","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.revmed.2011.12.011_bib0080","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/pds.1978","article-title":"Use of proton pump inhibitors and H2\u00a0blockers and risk of pneumonia in older adults: a population-based case-control study","volume":"19","author":"Dublin","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.revmed.2011.12.011_bib0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.amjmed.2009.05.032","article-title":"Recurrent community-acquired pneumonia in patients starting acid-suppressing drugs","volume":"123","author":"Eurich","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2011.12.011_bib0090","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1378\/chest.08-1634","article-title":"Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients","volume":"136","author":"Miano","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.revmed.2011.12.011_bib0095","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1001\/jama.294.23.2989","article-title":"Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease","volume":"294","author":"Dial","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2011.12.011_bib0100","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1503\/cmaj.060284","article-title":"Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy","volume":"175","author":"Dial","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.revmed.2011.12.011_bib0105","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2036.2006.03015.x","article-title":"Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea","volume":"24","author":"Yearsley","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2011.12.011_bib0110","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archinternmed.2010.89","article-title":"Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection","volume":"170","author":"Howell","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2011.12.011_bib0115","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1086\/508453","article-title":"Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study","volume":"43","author":"Lowe","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2011.12.011_bib0120","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/j.1572-0241.2007.01275.x","article-title":"Systematic review of the risk of enteric infection in patients taking acid suppression","volume":"102","author":"Leonard","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0125","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2125.2007.02927.x","article-title":"Proton pump inhibitor-induced acute interstitial nephritis","volume":"64","author":"H\u00e4rmark","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.5414\/CNP68065","article-title":"Proton pump inhibitors and the kidney: critical review","volume":"68","author":"Brewster","year":"2007","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2007.06.022","article-title":"Chronic proton pump inhibitor therapy and the risk of colorectal cancer","volume":"133","author":"Yang","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2011.12.011_bib0140","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1572-0241.2007.01665.x","article-title":"Proton pump inhibitors and the risk of colorectal cancer","volume":"103","author":"van Soest","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1365-2036.2000.00681.x","article-title":"Personal review: is profound acid inhibition safe?","volume":"14","author":"Waldum","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2011.12.011_bib0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1365-2036.2000.00750.x","article-title":"Personal review: alarmism or legitimate concerns about long-term suppression of gastric acid secretion?","volume":"14","author":"Yeomans","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2011.12.011_bib0155","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1038\/ajg.2009.369","article-title":"Use of proton pump inhibitors and risk of progression of Barrett's esophagus to neoplastic lesions","volume":"104","author":"Islami","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0160","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0016-5085(99)70064-8","article-title":"Omeprazole and dietary nitrate independently affect levels of vitamin C and nitrite in gastric juice","volume":"116","author":"Mowat","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2011.12.011_bib0165","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM199604183341603","article-title":"Atrophicgastritis and Helicobacter pylori infection in patients with refux esophagitis treated with omeprazole or fundoplication","volume":"334","author":"Kuipers","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2011.12.011_bib0170","first-page":"1775","article-title":"Could proton pump inhibitors cause cancer?","volume":"170","author":"Rosch","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.revmed.2011.12.011_bib0175","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/07315724.1994.10718452","article-title":"Effect of hypochlorhydria due to omeprazole treatment or atrophic gastritis on protein-bound vitamin B12\u00a0absorption [see comment]","volume":"13","author":"Saltzman","year":"1994","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.revmed.2011.12.011_bib0180","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/gut.39.1.54","article-title":"Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study","volume":"39","author":"Thorens","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2011.12.011_bib0185","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jclinepi.2003.08.015","article-title":"A case-control study on adverse effects: H2\u00a0blocker or proton pump inhibitor use and risk of vitamin B12\u00a0deficiency in older adults","volume":"57","author":"Valuck","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0190","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0002-9343(98)00087-4","article-title":"Effect of long-term gastric acid suppressive therapy on serum vitamin B12\u00a0levels in patients with Zollinger-Ellison syndrome","volume":"104","author":"Termanini","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2011.12.011_bib0195","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jn\/133.3.801","article-title":"Vitamin B-12\u00a0status is associated with bone mineral content and bone mineral density in frail elderly women but not in men","volume":"133","author":"Dhonukshe-Rutten","year":"2003","journal-title":"J Nutr"},{"key":"10.1016\/j.revmed.2011.12.011_bib0200","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2036.1998.00274.x","article-title":"Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy","volume":"12","author":"Stewart","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2011.12.011_bib0205","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1136\/gut.2006.108613","article-title":"Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis","volume":"56","author":"Hutchinson","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2011.12.011_bib0210","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/00004836-199206000-00005","article-title":"Serum iron, ferritin, and vitamin B12\u00a0during prolonged omeprazole therapy","volume":"14","author":"Koop","year":"1992","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0215","first-page":"25","article-title":"In brief: PPI's and hypomagnesemia","volume":"53","year":"2011","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.revmed.2011.12.011_bib0220","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/gut.39.5.649","article-title":"Marked increase in gastric acid secretory capacity after omeprazole treatment","volume":"39","author":"Waldum","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.revmed.2011.12.011_bib0225","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.gastro.2009.03.058","article-title":"Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy","volume":"137","author":"Reimer","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2011.12.011_bib0230","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0016-5085(99)70118-6","article-title":"Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status","volume":"116","author":"Gillen","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2011.12.011_bib0235","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2036.2004.02271.x","article-title":"Rebound acid hypersecretion after long-term inhibition of gastric acid secretion","volume":"21","author":"Fossmark","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2011.12.011_bib0240","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2036.2006.03084.x","article-title":"Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial","volume":"24","author":"Bj\u00f6rnsson","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2011.12.011_bib0245","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000236025","article-title":"Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial","volume":"81","author":"van der Velden","year":"2010","journal-title":"Digestion"},{"key":"10.1016\/j.revmed.2011.12.011_bib0250","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/jac\/dkg089","article-title":"A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution","volume":"51","author":"Johnson","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.revmed.2011.12.011_bib0255","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.healun.2009.03.006","article-title":"Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients","volume":"28","author":"Kofler","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.revmed.2011.12.011_bib0260","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0091270007313392","article-title":"Effects of acid-reducing agents on the pharmacokinetics of lopinavir\/ritonavir and ritonavir-boosted atazanavir","volume":"48","author":"Klein","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0265","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2146\/ajhp070226","article-title":"Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir","volume":"65","author":"Tappouni","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.revmed.2011.12.011_bib0270","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1592\/phco.28.1.42","article-title":"Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects","volume":"28","author":"Fang","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.revmed.2011.12.011_bib0275","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/01.aids.0000233573.41597.8a","article-title":"Effect of omeprazole on the pharmacokinetics of saquinavir-500mg formulation with ritonavir in healthy male and female volunteers","volume":"20","author":"Winston","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.revmed.2011.12.011_bib0280","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/11531320-000000000-00000","article-title":"Drug-drug interaction profiles of proton pump inhibitors","volume":"49","author":"Ogawa","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.revmed.2011.12.011_bib0285","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2125.1991.tb03953.x","article-title":"Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose","volume":"32","author":"Oosterhuis","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0290","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF00266355","article-title":"Influence of single- and multipledose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects","volume":"42","author":"Soons","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0295","doi-asserted-by":"crossref","first-page":"d2690","DOI":"10.1136\/bmj.d2690","article-title":"Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study","volume":"342","author":"Charlot","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2011.12.011_bib0300","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/hrt.2009.181107","article-title":"The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease","volume":"96","author":"W\u00fcrtz","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.revmed.2011.12.011_bib0305","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450\u00a0activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.revmed.2011.12.011_bib0310","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0016-5085(90)90963-2","article-title":"Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450","volume":"99","author":"Diaz","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2011.12.011_bib0315","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1053\/j.gastro.2010.08.023","article-title":"Safety of proton pump inhibitor exposure","volume":"139","author":"Yang","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.revmed.2011.12.011_bib0320","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijcard.2011.01.091","article-title":"Separate dosing of clopidogrel and omeprazole may improve platelet inhibition on dual antiplatelet therapy","volume":"149","author":"Chyrchel","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0325","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","article-title":"Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy","volume":"67","author":"Suzuki","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.revmed.2011.12.011_bib0330","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1542\/peds.2010-2719","article-title":"Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review","volume":"127","author":"van der Pol","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.revmed.2011.12.011_bib0335","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1365-2036.2011.04592.x","article-title":"Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia","volume":"33","author":"Hassall","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2011.12.011_bib0340","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.gastro.2009.05.015","article-title":"Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat","volume":"137","author":"McColl","year":"2009","journal-title":"Gastroenterology"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866311012847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866311012847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:30:30Z","timestamp":1759336230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866311012847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0248866311012847"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2011.12.011","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets ind\u00e9sirables des inhibiteurs de la pompe \u00e0 proton\u00a0: faut-il craindre de les prescrire au long cours\u00a0?","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2011.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}